Holen Sie sich die Stockscreener-App
0.52
5.45%
-0.03
Schlusskurs vom Vortag:
$0.55
Offen:
$0.55
24-Stunden-Volumen:
1.40M
Relative Volume:
0.10
Marktkapitalisierung:
$62.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-225.14M
KGV:
-0.2653
EPS:
-1.96
Netto-Cashflow:
$-192.27M
1W Leistung:
-13.33%
1M Leistung:
-50.48%
6M Leistung:
-45.29%
1J Leistung:
-85.47%
1-Tages-Spanne:
$0.5106
$0.565
1-Wochen-Bereich:
$0.5106
$0.631
52-Wochen-Spanne:
$0.3546
$3.93
Invivyd Inc Stock (IVVD) Company Profile
Firmenname
Invivyd Inc
Sektor
Branche
Telefon
(781) 819-0080
Adresse
1601 TRAPELO ROAD, WALTHAM
Vergleichen Sie IVVD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.52 | 62.38M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-26 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Eingeleitet | H.C. Wainwright | Buy |
Invivyd Inc Aktie (IVVD) Neueste Nachrichten
IVVD Stock Price and Chart — NASDAQ:IVVD - TradingView
Invivyd Appoints Ajay Royan to its Board of Directors - citybiz
Invivyd adds venture capitalist Ajay Royan to board By Investing.com - Investing.com South Africa
Invivyd Appoints Ajay Royan to Board of Directors - TipRanks
Invivyd adds venture capitalist Ajay Royan to board - Investing.com India
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors - The Manila Times
Major Investor Takes Board Seat: Invivyd Eyes Breakthrough Beyond COVID-19 Treatment - Stock Titan
Invivyd’s (IVVD) Buy Rating Reiterated at D. Boral Capital - Defense World
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - MSN
INVIVYD SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI - Business Wire
Invivyd Reports Strong Revenue Growth and Promising Developments - TipRanks
Invivyd earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 -March 20, 2025 at 08:12 am EDT - MarketScreener
Invivyd, Inc. SEC 10-K Report - TradingView
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Invivyd, Inc. Reports 48% Q4 Revenue Growth for PEMGARDA™ and Advances Next-Generation Antibody VYD2311 - Nasdaq
Invivyd, Inc. Full Year Loss Decreases, But Misses Estimates - Nasdaq
Invivyd (IVVD) Projected to Post Earnings on Thursday - Defense World
Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd reports pemivibart maintains efficacy against SARS-CoV-2 By Investing.com - Investing.com Canada
Invivyd reports pemivibart maintains efficacy against SARS-CoV-2 - Investing.com India
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 - The Manila Times
Invivyd's COVID Treatment Still Works Against Elusive LP.8.1 VariantCritical News for Immunocompromised Patients - StockTitan
Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody - Simply Wall St
Invivyd Inc [IVVD] Insider Activity: An Update for Investors - Knox Daily
Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD) - Armenian Reporter
The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine - Yahoo Finance
Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from D. Boral Capital - Defense World
Invivyd (NASDAQ:IVVD) Given “Buy” Rating at HC Wainwright - Defense World
FDA declines Invivyd's COVID-19 treatment EUA expansion By Investing.com - Investing.com Australia
FDA declines Invivyd’s COVID-19 treatment EUA expansion By Investing.com - Investing.com Nigeria
IVVD Stock: More Upside For Invivyd Inc (NASDAQ: IVVD)? - Marketing Sentinel
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients - Benzinga
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday - TradingView
Invivyd says FDA declines request to expand existing EUA of PEMGARDA - TipRanks
Sector Update: Health Care - TradingView
5 Stocks That More Than Doubled Halfway Through Q1 - Zacks Investment Research
Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
Invivyd shares drop as FDA declines company's COVID-19 treatment EUA expansion - MSN
FDA declines Invivyd’s COVID-19 treatment EUA expansion - Investing.com India
FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Chang - The Manila Times
Can PEMGARDA Still Succeed? FDA Blocks COVID Treatment Expansion but Keeps Prevention Approval - StockTitan
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 5.2% in January - Armenian Reporter
Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far - MSN
10 Micro and Small-Cap Firms Drive Year-to-Date Gains - Insider Monkey
Invivyd, Inc. (NASDAQ:IVVD) Sees Significant Growth in Short Interest - MarketBeat
Finanzdaten der Invivyd Inc-Aktie (IVVD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Invivyd Inc-Aktie (IVVD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | Director |
Dec 27 '24 |
Sale |
0.52 |
83,744 |
43,647 |
3,256,776 |
| MCGUIRE TERRANCE | Director |
Dec 30 '24 |
Sale |
0.48 |
86,545 |
41,784 |
3,170,231 |
| MCGUIRE TERRANCE | Director |
Dec 20 '24 |
Sale |
0.42 |
119,805 |
50,725 |
3,568,274 |
| MCGUIRE TERRANCE | Director |
Dec 26 '24 |
Sale |
0.54 |
83,817 |
45,563 |
3,340,520 |
| MCGUIRE TERRANCE | Director |
Dec 24 '24 |
Sale |
0.51 |
68,161 |
34,503 |
3,424,337 |
| MCGUIRE TERRANCE | Director |
Dec 23 '24 |
Sale |
0.45 |
75,776 |
34,076 |
3,492,498 |
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):